NCT05439603View on ClinicalTrials.gov

ANC-501 in the Treatment of Adults With Major Depressive Disorder

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

September 19, 2022

Primary Completion Date

August 14, 2023

Study Completion Date

October 18, 2023

Conditions
Major Depressive Disorder
Interventions
DRUG

ANC-501

Five 10 mg capsules per day

Trial Locations (8)

10016

Clinilabs Drug development Corporation, New York

10314

Richmond Behavioral Associates, Staten Island

32807

Combined Research Orlando, Orlando

33319

Innovative Clinical Research, Inc., Lauderhill

33770

Florida Behavioral Medicine, Largo

73013

Conrad Clinical Research, Edmond

92868

ATP Clinical Research, Orange

07724

Clinilabs Drug Development Corporation, Eatontown

All Listed Sponsors
lead

Ancora Bio, Inc. d/b/a EmbarkNeuro, Inc.

INDUSTRY